Johnson & Johnson PE Ratio 2006-2018 | JNJ

Current and historical p/e ratio for Johnson & Johnson (JNJ) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Johnson & Johnson PE ratio as of March 18, 2019 is 16.77.
Johnson & Johnson PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-03-18 137.17 24.45
2018-12-31 128.20 $5.61 22.85
2018-09-30 136.39 $0.50 272.79
2018-06-30 118.99 $0.43 276.71
2018-03-31 124.74 $0.38 328.27
2017-12-31 135.14 $0.39 346.52
2017-09-30 124.99 $5.76 21.70
2017-06-30 126.38 $5.92 21.35
2017-03-31 118.20 $5.95 19.87
2016-12-31 108.63 $5.88 18.47
2016-09-30 110.62 $5.65 19.58
2016-06-30 112.83 $5.32 21.21
2016-03-31 99.94 $5.50 18.17
2015-12-31 94.20 $5.49 17.16
2015-09-30 84.98 $5.23 16.25
2015-06-30 88.03 $5.69 15.47
2015-03-31 90.21 $5.59 16.14
2014-12-31 93.12 $5.70 16.34
2014-09-30 94.31 $6.04 15.61
2014-06-30 91.94 $5.42 16.96
2014-03-31 85.73 $5.24 16.36
2013-12-31 79.36 $4.82 16.47
2013-09-30 74.60 $4.50 16.58
2013-06-30 73.34 $4.51 16.26
2013-03-31 69.12 $3.68 18.78
2012-12-31 58.96 $3.87 15.23
2012-09-30 57.45 $3.04 18.90
2012-06-30 55.82 $3.14 17.78
2012-03-31 53.98 $3.64 14.83
2011-12-31 53.20 $3.48 15.29
2011-09-30 51.19 $4.10 12.48
2011-06-30 52.99 $4.18 12.68
2011-03-31 46.79 $4.41 10.61
2010-12-31 48.41 $4.78 10.13
2010-09-30 48.08 $4.87 9.87
2010-06-30 45.40 $4.84 9.38
2010-03-31 49.67 $4.76 10.43
2009-12-31 48.69 $4.40 11.07
2009-09-30 45.67 $4.58 9.97
2009-06-30 42.26 $4.55 9.29
2009-03-31 38.79 $4.57 8.49
2008-12-31 43.76 $4.57 9.57
2008-09-30 50.27 $4.42 11.37
2008-06-30 46.39 $4.13 11.23
2008-03-31 46.44 $4.01 11.58
2007-12-31 47.44 $3.63 13.07
2007-09-30 46.44 $3.55 13.08
2007-06-30 43.27 $3.61 11.99
2007-03-31 42.04 $3.51 11.98
2006-12-31 45.79 $3.73 12.28
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $368.014B $81.581B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $248.889B 13.94
Merck (MRK) United States $219.335B 18.74
Novartis AG (NVS) Switzerland $215.223B 18.31
Eli Lilly (LLY) United States $129.676B 22.52
Novo Nordisk (NVO) Denmark $125.720B 20.34
AbbVie (ABBV) United States $118.965B 10.20
Sanofi (SNY) France $112.638B 13.90
AstraZeneca (AZN) United Kingdom $107.851B 12.31
GlaxoSmithKline (GSK) United Kingdom $100.439B 13.19
Bristol-Myers Squibb (BMY) United States $81.405B 12.53